The FDA approved Lisraya (brepocitinib), the first oral drug…

The FDA approved Lisraya (brepocitinib), the first oral drug indicated to treat dermatomyositis in adults Dermatomyositis is a rare autoimmune attack on muscle and skin. For decades people borrowed drugs meant for other diseases.